NMTR - 9 Meters drug effective in treating rare COVID-19 complication in children

Larazotide, in development by 9 Meters Biopharma (NMTR), led to a significant drop in inflammatory mediators in an infant with multisystem inflammatory syndrome in children (MIS-C).MIS-C is a serious, rare complication following COVID-19 infection with symptoms that include persistent fever, gastrointestinal symptoms, and myocardial dysfunction.A case study, published in The Journal of Clinical Investigation, found that after the 17-month-old was treated with larazotide, SARS-CoV-2 nucleocapsid protein level dropped by 98%, C-reactive protein by 85%, and circulating spike protein by 90%, leading to lower levels of inflammation and clinical stabilization.The authors say the results provide translational evidence for the candidate's ability to restore gut mucosal barrier integrity.Larazotide is already in phase 3 for treatment of celiac disease for adults.9 Meters shares are up 2.1% to $1.22 in premarket trading.

For further details see:

9 Meters drug effective in treating rare COVID-19 complication in children